Radiolabeling of Theranostic Nanosystems

Show full item record



Permalink

http://hdl.handle.net/10138/340710

Citation

Das , S , Imlimthan , S , Airaksinen , A & Sarparanta , M 2021 , Radiolabeling of Theranostic Nanosystems . in F Fontana & H A Santos (eds) , Bio-Nanomedicine for Cancer Therapy . 1 edn , Advances in Experimental Medicine and Biology , vol. 1295 , Springer Nature Switzerland AG , Cham , pp. 49-76 . https://doi.org/10.1007/978-3-030-58174-9_3

Title: Radiolabeling of Theranostic Nanosystems
Author: Das, Sudeep; Imlimthan, Surachet; Airaksinen, Anu; Sarparanta, Mirkka
Other contributor: Fontana, Flavia
Santos, Hélder A.
Contributor organization: Department of Chemistry
Tracers in Molecular Imaging (TRIM)
Doctoral Programme in Chemistry and Molecular Sciences
Helsinki In Vivo Animal Imaging Platform (HAIP)
Doctoral Programme in Drug Research
Publisher: Springer Nature Switzerland AG
Date: 2021-02-05
Language: eng
Number of pages: 28
Belongs to series: Bio-Nanomedicine for Cancer Therapy
Belongs to series: Advances in Experimental Medicine and Biology
ISBN: 978-3-030-58173-2
978-3-030-58174-9
ISSN: 0065-2598
DOI: https://doi.org/10.1007/978-3-030-58174-9_3
URI: http://hdl.handle.net/10138/340710
Abstract: In the recent years, progress in nanotechnology has significantly contributed to the development of novel pharmaceutical formulations to overcome the drawbacks of conventional treatments and improve the therapeutic outcome in many diseases, especially cancer. Nanoparticle vectors have demonstrated the potential to concomitantly deliver diagnostic and therapeutic payloads to diseased tissue. Due to their special physical and chemical properties, the characteristics and function of nanoparticles are tunable based on biological molecular targets and specific desired features (e.g., surface chemistry and diagnostic radioisotope labeling). Within the past decade, several theranostic nanoparticles have been developed as a multifunctional nanosystems which combine the diagnostic and therapeutic functionalities into a single drug delivery platform. Theranostic nanosystems can provide useful information on a real-time systemic distribution of the developed nanosystem and simultaneously transport the therapeutic payload. In general, the diagnostic functionality of theranostic nanoparticles can be achieved through labeling gamma-emitted radioactive isotopes on the surface of nanoparticles which facilitates noninvasive detection using nuclear molecular imaging techniques, such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT), meanwhile, the therapeutic effect arises from the potent drug released from the nanoparticle. Moreover, some radioisotopes can concurrently emit both gamma radiation and high-energy particles (e.g., alpha, beta, and Auger electrons), prompting the use either alone for radiotheranostics or synergistically with chemotherapy. This chapter provides an overview of the fundamentals of radiochemistry and relevant radiolabeling strategies for theranostic nanosystem development as well as the methods for the preclinical evaluation of radiolabeled nanoparticles. Furthermore, preclinical case studies of recently developed theranostic nanosystems will be highlighted.
Subject: BIOMARKER
DRUG-DELIVERY SYSTEM
MICROSPHERES
MR
NANOPARTICLES
Nuclear imaging Molecular imaging
PET
RADIOIMMUNOTHERAPY
RADIOIODINATION
RETENTION
Radiochemistry
Radiolabeling
SENESCENCE
Theranostic nanosystem Nanotheranostic
116 Chemical sciences
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: acceptedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
Radiolabeling_of_theranostic_nanosystems.pdf 2.245Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record